胱冬肽酶募集结构域与弥漫性大B细胞淋巴瘤  

Caspase recruitment domain 11 and diffuse large B-cell lymphoma

作　　者：刘方方(综述)[1] 葛军辉(综述)[1] 刘惠敏(审校)[2] 侯健(审校)[2] 

机构地区：[1]第二军医大学附属长征医院病理科,上海200003 [2]第二军医大学附属长征医院血液科,上海200003

出　　处：《白血病．淋巴瘤》2010年第11期702-704,共3页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金（81071865）;上海市科学技术委员会科研计划项目（10411963700）

摘　　要：弥漫性大B细胞淋巴瘤（DLBCL）是恶性淋巴瘤中最常见的类型,其形态学、免疫表型、遗传学特点及临床预后各异.目前国内外绝大多数学者认为,NF-κB持续活化是活化B细胞DLBCL（ABC-DLBCL）预后不良的原因之一,而胱冬肽酶募集结构域（CARD11）是NF-κB信号通路中的重要蛋白分子,丰富的临床前资料也证明了CARD11在DLBCL中的重要性.对CARD11与NF-κB及DLBCL的相关性进行概括,以更清楚地了解DLBCL的发病机制和治疗靶向.Diffuse large B-cell lymphoma （DLBCL） represents the most common type of malignant lymphoma. DLBCL is heterogeneous with respect to morphology, immunophenotype, biology, clinical presentation and outcome. Constitutive activity of the NF-κB pathway may contribute to the poor prognosis of patients with activated B cell-like （ABC） subgroup of DLBCL, caspase recruitment domain 11 （CARD11） is the important signal protein in the signaling pathway of NF-κB. Furthermore, various pre-clinical data have proved the importance of CARD11 in DLBCL. This review summarizes the biological characteristics of CARD11, and its relationship with NF-κB signaling transduction pathway and the outcome of DLBCL, so that we can better understanding the pathogenesis and new therapeutic target of DLBCL.

关 键 词：淋巴瘤 大细胞 弥漫型 NF-κB 治疗 脱冬肽酶募集结构域 

分 类 号：R733.4[医药卫生—肿瘤]